Comfrey Side Effects

Reported Comfrey side effects

Comfrey's side effect profile is fundamentally bimodal: topical use on intact skin with standardized low-PA preparations has a mild and favorable local adverse-event profile, while oral use (or application to broken skin, mucous membranes, or prolonged high-dose topical use) carries the potentially fatal pyrrolizidine-alkaloid hepatotoxicity signal. Any honest discussion of comfrey side effects must distinguish these two contexts — the topical use is appropriately considered reasonably safe within defined limits; the oral use is appropriately considered unsafe at any dose. TOPICAL SIDE EFFECTS (intact skin, low-PA standardized preparations, ≤10 days per course) Local skin effects — uncommon and typically mild. Contact dermatitis, erythema, pruritus, or irritation at the application site occurs in a small minority of users — across clinical trials, rates are in the range of 1-4% and are generally mild, transient, and resolve with discontinuation. Sensitive individuals or those with pre-existing atopic dermatitis, eczema, or other chronic skin conditions may be more susceptible to local reactions. Skin reactions may reflect hypersensitivity to comfrey constituents, to excipients in the ointment base, or to preservatives. Photosensitivity — rare but reported. Some topical botanical preparations produce photosensitive reactions; comfrey is not considered a common photosensitizer but isolated cases exist. If new sun-exposure-related skin reactions develop on treated areas, discontinue and avoid further exposure. Allergic reactions. True allergic contact dermatitis (type IV hypersensitivity) to comfrey or ointment excipients can occur. Presentation: delayed (24-72 hours post-application), erythematous, pruritic, sometimes vesicular rash confined to treated areas and perhaps beyond. Management: discontinue, topical low-potency corticosteroid may help, avoid re-exposure. Type I (immediate) hypersensitivity with urticaria, angioedema, or anaphylaxis is very rare with topical comfrey but has been reported rarely with herbal contact allergens. Systemic effects from topical use on intact skin — should be essentially absent with low-PA products. Modern standardized low-PA topical products (Kytta-Salbe f, Traumaplant) at recommended doses produce very low systemic PA exposure through intact skin, well below clinically meaningful hepatotoxic thresholds over the recommended 10-day course. Hepatotoxicity from proper topical use on intact skin has not been documented in the clinical trial literature — but this is contingent on using low-PA formulations, limiting duration, and using intact skin only. The safety assumption fails if these conditions are violated. ORAL OR MUCOSAL SIDE EFFECTS (not recommended under any circumstances, described here for honesty) Hepatic veno-occlusive disease / sinusoidal obstruction syndrome (VOD / SOS) — the central catastrophic toxicity of oral comfrey. As discussed in the Mechanism and Clinical Evidence sections, chronic oral comfrey ingestion causes a distinct and serious form of liver injury: reactive pyrroles from hepatic CYP3A4 metabolism alkylate hepatic sinusoidal endothelial cells, producing sinusoidal destruction, fibrous obliteration of small hepatic veins, and progressive hepatic dysfunction. Presentation: insidious onset over weeks to months of tender painful hepatomegaly, weight gain from ascites, jaundice, elevated liver enzymes, hyperbilirubinemia, and in severe cases portal hypertension and liver failure. Mortality in severe VOD is significant — 20-50% in some case series — and survivors often have residual chronic liver disease. The syndrome is dose-dependent over time: higher cumulative PA exposure produces earlier and more severe injury. Specific at-risk patterns include daily comfrey tea consumption over months to years, chronic comfrey tincture use, and infant exposure via maternal breastfeeding by mothers consuming PA-containing herbs. Acute hepatotoxicity from high single doses. While chronic exposure is the more common pattern, sufficiently high single oral doses of PAs can produce acute hepatotoxicity with elevated transaminases, jaundice, and constitutional symptoms. Outbreaks of acute PA poisoning from contaminated grain supplies (Afghanistan heliotropium-contaminated wheat outbreaks) have demonstrated this pattern at population scale. Carcinogenicity — long-term oral exposure concern. Long-term rodent feeding studies of comfrey and specific PAs have produced hepatocellular carcinoma in various exposure protocols (Hirono and colleagues, 1970s-1980s). IARC has classified several individual PAs as Group 2B (possibly carcinogenic to humans). While clear human epidemiologic evidence of comfrey-associated hepatocellular cancer is not robust (limited by confounding and difficulty attributing lifetime exposure), the animal signal combined with the hepatotoxic mechanism supports appropriate caution. This is one basis — along with the more immediate VOD risk — for regulatory restriction on oral use. Pulmonary hypertension — rare but reported. Some PAs alkylate pulmonary endothelial cells in addition to hepatic cells, producing pulmonary arterial hypertension in certain exposure contexts. The clinical relevance for comfrey users is minor relative to the hepatic risk but is part of the broader PA toxicology. Fetal and neonatal harm. Trans-placental PA exposure produces neonatal VOD; the Bach 1989 gordolobo-tea infant case is the classic example (maternal PA consumption during pregnancy and lactation resulted in fatal infant VOD). Maternal breast milk excretes PAs; nursing infants of mothers consuming PA-containing herbs are at risk. Both pregnancy and breastfeeding are therefore absolute contraindications to comfrey internal use and to any topical use on nipples or areas with skin that may transfer material. Chronic progressive liver disease in long-term oral users. Beyond acute VOD, long-term oral PA exposure can produce progressive hepatic fibrosis, cirrhosis, and associated complications (esophageal varices, encephalopathy, hepatorenal syndrome). This evolution has been described in chronic users of PA-containing herbal teas and preparations. Application-on-broken-skin / mucous membrane side effects — approaching oral risk profile. Topical application to broken skin, open wounds, ulcers, abrasions, burns, mucous membranes (oral, nasal, genital, rectal), or under occlusion substantially increases systemic PA absorption. The resulting exposure approaches oral use in hepatotoxic potential and is not considered safe. Historical traditional practice of applying comfrey poultices to open wounds for "wound healing" is specifically contraindicated in modern safe practice — the PA exposure from this use pattern is too high. Extended continuous topical use — cumulative exposure concern. Modern safety guidance limits continuous topical use to ≤10 days per course and ≤4-6 weeks cumulatively per year. Extended continuous application beyond these durations, even on intact skin with low-PA formulations, increases cumulative systemic PA burden and carries increasing risk of hepatotoxicity. Users who chronically apply comfrey ointment daily for months or years for persistent joint pain are operating outside the safety envelope validated by clinical trials and regulatory guidance. Quality and contamination concerns. Uncontrolled "raw comfrey" herbal products, homemade teas, and tinctures have unpredictable and frequently very high PA content — often orders of magnitude higher than the ≤0.35 µg PA/100 g reference for commercial low-PA topical products. Traditional herbalism's use of whole-plant preparations without PA-content analysis is therefore uniformly higher-risk than modern standardized products. Wild-harvested material can be Symphytum × uplandicum (Russian comfrey) or another high-PA species misidentified as S. officinale. Drug interactions — relevant for both topical and any internal use CYP3A4 interactions — direct relevance to PA bioactivation. Any PAs absorbed systemically are bioactivated by hepatic CYP3A4. Drugs that induce CYP3A4 (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort, efavirenz, nevirapine, some glucocorticoids at high doses) accelerate PA bioactivation and may worsen hepatotoxicity. Drugs that inhibit CYP3A4 (clarithromycin, erythromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice) slow bioactivation — but this does not make comfrey safer; inhibited metabolism may simply prolong PA circulation with uncertain net effect. Concurrent use of strong CYP3A4-inducing drugs plus comfrey is a specific high-risk combination. Hepatotoxic drug combinations. Any medication with independent hepatotoxic potential — acetaminophen at high or chronic doses, amiodarone, statins (rarely), methotrexate, isoniazid, valproate, nitrofurantoin, many TCM herbs — combined with comfrey represents additive hepatic insult. Patients on polypharmacy involving hepatotoxic agents should avoid even topical comfrey, and categorically should avoid oral use. Anticoagulants and antiplatelets. Comfrey does not have strong direct effects on coagulation at topical doses. However, any liver injury affects coagulation factor synthesis; in patients on warfarin or DOACs with concurrent liver stress, interactions become complex and unpredictable. Interaction with alcohol and recreational substances. Alcohol is an independent hepatotoxin; concurrent heavy alcohol use plus any comfrey exposure (even topical) is a bad combination. Anabolic steroids, various recreational compounds, and supplements with independent hepatotoxic potential similarly stack unfavorably. Signs warranting immediate medical evaluation — comfrey users, especially if any oral exposure. (1) Right upper quadrant pain or tender hepatomegaly; (2) unexplained weight gain or abdominal distension (possible ascites); (3) jaundice (yellowing of skin, sclerae, mucous membranes); (4) dark urine or pale stools; (5) fatigue, anorexia, nausea out of proportion to other causes; (6) leg edema; (7) confusion or somnolence (possible encephalopathy); (8) gastrointestinal bleeding (possible variceal). Any of these signs in a comfrey user — topical or oral — warrants urgent medical evaluation with liver function testing, imaging, and specialist referral as indicated. Pediatric special risk. Children are particularly susceptible to PA hepatotoxicity for multiple reasons: higher relative hepatic metabolic rate for some substrates, smaller body mass leading to higher relative exposure, and developmental vulnerability of hepatic tissue. Comfrey should not be used orally or topically in children <6 years old; topical use in older children should only be with specific pediatric formulations under medical guidance, and oral use is contraindicated. Summary — expected vs concerning. Expected with topical use on intact skin, low-PA product, ≤10 days per course: no symptoms or mild local irritation resolving with discontinuation; measurable symptomatic improvement in treated musculoskeletal area. Concerning: any systemic symptoms (fatigue, jaundice, right upper quadrant pain, weight gain, edema); any skin reaction beyond mild transient erythema; application on broken skin or mucous membranes; duration beyond 10 days per course; repeated courses totaling >6 weeks/year; oral exposure in any form; pediatric use; use during pregnancy or breastfeeding. Any concerning sign warrants discontinuation and medical evaluation. Oral comfrey exposure, even accidentally via mislabeled or misidentified product, warrants specific evaluation for VOD/SOS with liver function testing, right upper quadrant ultrasound, and possibly hepatology referral depending on exposure magnitude and patient factors.

When to continue, reduce, or stop Comfrey

Comfrey contraindications

Absolute contraindications — NO COMFREY USE WHATSOEVER Pregnancy — absolute contraindication. Comfrey is absolutely contraindicated in pregnancy for any use, any dose, any duration, any route. Pyrrolizidine alkaloid transplacental exposure can cause fetal hepatotoxicity, neonatal VOD/SOS, and potentially fatal infant liver disease. The Bach 1989 infant gordolobo-tea case is the classic tragic example — an infant developed fatal VOD after maternal consumption of PA-containing herbal tea. Even topical comfrey use on intact skin during pregnancy is not considered safe because residual systemic absorption plus transplacental PA transfer is not acceptable risk during a critical developmental period. Women planning pregnancy should discontinue comfrey use at least several weeks before conception. Breastfeeding / lactation — absolute contraindication. Pyrrolizidine alkaloids are excreted in breast milk and can cause neonatal VOD in nursing infants. No topical or oral use is acceptable during lactation. Women who have used comfrey before learning of pregnancy or lactation should discontinue immediately and inform their obstetric or pediatric clinician. Children <6 years old — absolute contraindication. Pediatric hepatic metabolism and developmental vulnerability make children particularly susceptible to PA hepatotoxicity. Children 6-12 may use specific pediatric topical formulations only under medical guidance; younger children should not use comfrey in any form. Accidental ingestion by children is a medical emergency warranting immediate evaluation — keep all comfrey products out of reach. Pre-existing liver disease — absolute contraindication for internal use and strong relative contraindication for topical use. Patients with any significant liver disease (cirrhosis, chronic hepatitis B or C, autoimmune hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease with fibrosis, prior drug-induced liver injury, prior PA exposure, any cause of portal hypertension) should not use comfrey in any form. The residual risk from even topical low-PA products combined with impaired hepatic reserve is not acceptable when safer alternatives exist. Known or suspected hypersensitivity to comfrey, Symphytum species, Boraginaceae family plants, allantoin, or any comfrey product excipients — discontinue immediately if allergic symptoms develop; do not retry. Oral use in any circumstances — absolute contraindication. No oral comfrey tea, tincture, capsule, decoction, or other internal preparation is endorsed in this entry. The FDA 2001 advisory, Canadian 1989 action, UK 2002 restrictions, German regulatory evolution to external-only, Australian restrictions, and equivalent international actions reflect consensus on oral safety that this entry follows. Application to broken skin, open wounds, ulcers, burns, abrasions, or mucous membranes — absolute contraindication. Percutaneous PA absorption through compromised skin barrier is dramatically higher than through intact skin and is not considered safe. Traditional practice of applying comfrey to open wounds for "wound healing" is specifically contraindicated in modern safe practice. For wound care, use appropriate medical wound-care products under medical guidance. Relative contraindications — require medical guidance before use Complex polypharmacy involving hepatically-metabolized drugs: Patients on multiple medications metabolized by CYP3A4, or on known hepatotoxic drugs (amiodarone, methotrexate, isoniazid, valproate, certain statins at high doses, nitrofurantoin, various chemotherapy agents, various TCM herbs with hepatotoxic potential) should discuss comfrey use with their physician or pharmacist. In most cases the recommendation will be to avoid comfrey and use safer topical alternatives (boswellia systemic, topical diclofenac, capsaicin, arnica). Strong CYP3A4 inducers: Patients on rifampin, phenytoin, carbamazepine, phenobarbital, efavirenz, nevirapine, St. John's wort, or other strong CYP3A4 inducers should avoid comfrey. CYP3A4 induction accelerates PA bioactivation to reactive pyrroles, potentially increasing hepatotoxicity risk even from the residual systemic absorption of topical products. Heavy alcohol use: Alcohol is an independent hepatotoxin; concurrent heavy alcohol use and comfrey use (even topical) represents additive hepatic insult. Patients with active alcohol use disorder or regular heavy drinking should avoid comfrey. Concurrent use of other PA-containing herbs: Coltsfoot (Tussilago farfara), borage (Borago officinalis — though borage oil without whole herb may have minimal PA content), butterbur (Petasites hybridus — unless specifically PA-free standardized extract), heliotrope, senecio, crotalaria species, and other Boraginaceae and Asteraceae PA-containing herbs stack with comfrey for total PA exposure. Avoid concurrent use. Active or recent prior PA exposure: Patients with recent high-dose PA exposure (outbreaks, intentional use of PA-containing herbs, livestock or agricultural occupational exposure) should avoid additional PA exposure regardless of form. Transplant recipients on immunosuppression (tacrolimus, cyclosporine, sirolimus, mycophenolate): These agents have narrow therapeutic windows and hepatic processing concerns; avoid comfrey. Active chemotherapy: Oncology patients should avoid any non-essential herbal exposure including topical comfrey unless specifically approved by the oncology team; hepatotoxic potential of chemotherapy stacks unfavorably with any additional hepatic insult. Patients with concurrent autoimmune hepatitis, primary biliary cholangitis, or other autoimmune liver disease: Avoid. Prior history of idiosyncratic drug-induced liver injury: Patients with prior DILI from any agent have elevated risk of similar reactions to PA-related metabolites; avoid. Hereditary or acquired conditions predisposing to hepatic injury: Wilson disease, hemochromatosis with hepatic involvement, alpha-1 antitrypsin deficiency, porphyria, and similar conditions warrant conservative approaches; avoid. Known mechanical limitations preventing safe topical application: Severe skin breakdown, active dermatitis in potential application area, recent skin grafting, or surgical wound areas should avoid topical application until fully healed. Bleeding disorders or recent major hemorrhage: Comfrey's direct bleeding risk is small, but liver injury affects coagulation factor synthesis; patients with baseline coagulation concerns should use alternatives. Planned elective surgery within 7-14 days: Discontinue topical comfrey 7-14 days before elective surgery for general conservative practice — clean baseline LFTs and removal of any residual PA exposure before anesthesia and surgical stress. Planned blood donation: Although comfrey has not been specifically flagged by blood collection agencies, conservative practice is to avoid recent herbal-medication use before donation; follow collection agency guidance. Situations warranting medical consultation before any use Any history of liver disease of any cause. Any current hepatically-processed medication, particularly with hepatotoxic potential. Pregnancy, trying to conceive, or breastfeeding. Children of any age needing topical musculoskeletal support — alternatives are generally preferred. Significant musculoskeletal injury or persistent symptoms — medical evaluation takes precedence over self-directed herbal care. Skin conditions in or near the proposed application area. Active alcohol use disorder or heavy alcohol consumption. Complex medical history involving autoimmune disease, transplant, malignancy, or chronic organ disease. Symptoms warranting immediate medical attention during or after comfrey use Jaundice — yellowing of skin, sclerae (eye whites), mucous membranes. Right upper quadrant abdominal pain or tenderness. Tender or enlarged liver palpable below the right costal margin. Dark urine (cola-colored) or pale stools. Unexplained weight gain or abdominal distension (possible ascites from portal hypertension). New leg or ankle swelling (possible hepatic or cardiac cause). Confusion, disorientation, or somnolence (possible hepatic encephalopathy). Gastrointestinal bleeding (black tarry stools, vomiting blood — possible variceal). Persistent severe fatigue, anorexia, or nausea out of proportion to other causes. Fever with other hepatic symptoms. Severe or spreading skin reaction at application site. Systemic allergic symptoms (urticaria, wheeze, facial swelling, anaphylaxis) — immediate emergency care. Do NOT continue comfrey in the presence of any of these symptoms — discontinue, do not reapply, and seek medical evaluation urgently. Bring the product label/container to the medical appointment to facilitate PA exposure assessment. Legal and regulatory status United States: The FDA issued a July 2001 advisory to supplement manufacturers and distributors calling for removal of oral comfrey products from the market. Topical comfrey products remain legally available as dietary supplements / cosmetics under DSHEA but cannot make disease treatment claims; oral comfrey products have largely exited the legitimate market (some "traditional" or imported products may still be found but are outside mainstream commerce). Commercial low-PA topical products can be obtained via import or specialty retailers. Canada: Health Canada restricted oral comfrey products in 1989; topical products remain available under the Natural Health Products regulations with specific PA limits and labeling requirements. United Kingdom: UK regulators restricted oral comfrey products in 2002; topical products remain available with specifications. Germany: The Commission E monograph originally permitted limited internal use but has evolved to permit only external topical use on intact skin, with specific daily total-PA exposure limits (typically ≤1 µg PA/day for external use, ≤0.1 µg/day for any permitted internal use — though essentially no commercial internal products remain). Australia: The Therapeutic Goods Administration (TGA) has restricted oral comfrey and tightened specifications for topical products. European Union: Various national regulators have generally aligned on external-only use with PA content specifications; the EFSA has issued reports on PA dietary exposure more broadly. Not a CITES concern: Unlike pygeum, there are no endangered species or CITES-related sustainability concerns for comfrey. Quality variability and the key regulatory concern: The topical comfrey market includes well-regulated European phytomedicines with rigorous PA specifications and less-regulated supplement-market products with variable quality. Consumers should prefer products with explicit PA content disclosure (≤0.35 µg/100 g ointment), allantoin content, GMP manufacturing, and batch analysis availability. Uncharacterized products, "whole-plant" preparations without PA testing, homemade preparations, and any oral comfrey products are outside the modern safety framework. Not medical advice: This content is educational. Specific use decisions — particularly regarding whether to use topical comfrey at all, duration and frequency of use, management of any concerning symptoms, and interactions with pre-existing medical conditions or other treatments — warrant individualized clinician involvement. Comfrey represents one of the clearest examples in modern herbal medicine where traditional use and modern safety data diverge significantly; respect the modern safety framework and use topical products only within validated limits, or choose alternative approaches entirely.

Why vendor quality drives Comfrey side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Comfrey side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .